Look up any medication to see its FAA medical certification status, pathway requirements, and practical guidance for pilots. Based on publicly available FAA guidance including the AME Guide and Do-Not-Issue/Do-Not-Fly tables.
These medications are generally compatible with FAA medical certification. Your AME can typically issue your certificate at the time of exam.
Zestril, Prinivil
Lisinopril and other ACE inhibitors are generally compatible with FAA medical certification. Most AMEs can issue your certificate at the time of exam if blood pressure is well-controlled and there are no significant side effects.
View details →Norvasc
Amlodipine is generally acceptable for FAA medical certification. As a peripheral-acting calcium channel blocker, it is not on the Do Not Issue list. Report it on your application and ensure blood pressure is controlled.
View details →Lipitor
Atorvastatin and other statin medications are generally compatible with FAA medical certification. AMEs can typically issue certificates at the time of exam. Report the medication on your application and note any side effects.
View details →Lopressor, Toprol-XL
Metoprolol is generally acceptable for pilots when used for hypertension. The underlying cardiac condition being treated may require additional evaluation. Beta blockers used post-cardiac event require Special Issuance.
View details →Cozaar
Losartan and other ARBs (angiotensin receptor blockers) are generally compatible with FAA medical certification for hypertension treatment.
View details →Prilosec
Omeprazole and other PPIs are generally acceptable for FAA medical certification when used for GERD or acid reflux. The underlying condition should be stable and not cause symptoms that could impair flight safety.
View details →Synthroid, Levoxyl
Levothyroxine for hypothyroidism is generally compatible with FAA certification. Pilots must demonstrate stable thyroid levels (TSH within normal range) and be free of symptoms.
View details →Advil, Motrin
Ibuprofen is generally acceptable for pilots when used as directed. The FAA primarily requires that the underlying condition being treated does not itself disqualify you, and that you are not experiencing side effects that affect flight safety.
View details →Tylenol
Acetaminophen is one of the most commonly used OTC medications among pilots. It is generally acceptable with no required wait time, provided the underlying condition being treated is not disqualifying.
View details →Zyrtec
Cetirizine is an acceptable second-generation antihistamine for pilots. However, the FAA requires a grounding period after each dose to ensure no sedating side effects before flying.
View details →Claritin
Loratadine is generally the preferred antihistamine for pilots. Non-sedating in most individuals, but the FAA still recommends a ground trial before flying to confirm no individual sedation response.
View details →Zocor
Simvastatin is generally compatible with FAA certification. Same pathway as other statins — report it, ensure no significant muscle-related side effects.
View details →Crestor
Rosuvastatin is generally compatible with FAA medical certification. Like other statins, report the medication and ensure no significant muscle-related side effects such as rhabdomyolysis.
View details →Pravachol
Pravastatin is generally compatible with FAA certification. It has a lower risk of muscle-related side effects compared to some other statins, making it a common choice among pilots.
View details →Vasotec
Enalapril is an ACE inhibitor generally compatible with FAA medical certification. Blood pressure must be well-controlled and the pilot should not experience significant side effects such as dizziness or persistent cough.
View details →Altace
Ramipril is an ACE inhibitor acceptable for FAA certification when blood pressure is controlled. Report any side effects such as dizziness or dry cough to your AME.
View details →Lotensin
Benazepril is an ACE inhibitor generally compatible with FAA certification. Same pathway as other ACE inhibitors — report the medication and ensure blood pressure is well-controlled.
View details →Diovan
Valsartan is an ARB generally compatible with FAA medical certification for hypertension. Report on your application and ensure blood pressure is controlled.
View details →Avapro
Irbesartan is an ARB acceptable for FAA certification. Like other ARBs, it is not on the Do Not Issue list and AMEs can issue certificates when blood pressure is well-controlled.
View details →Benicar
Olmesartan is an ARB generally compatible with FAA certification. Standard antihypertensive pathway applies — report medication and demonstrate controlled blood pressure.
View details →Atacand
Candesartan is an ARB acceptable for FAA medical certification. Report on your application and ensure blood pressure is well-controlled with no significant side effects.
View details →Micardis
Telmisartan is an ARB generally compatible with FAA certification. Same pathway as losartan and other ARBs — report and demonstrate controlled blood pressure.
View details →Cardizem, Tiazac
Diltiazem is a calcium channel blocker generally acceptable for FAA certification when used for hypertension. If prescribed for arrhythmia, the underlying cardiac condition may require Special Issuance evaluation.
View details →Procardia, Adalat
Nifedipine is a calcium channel blocker generally acceptable for FAA certification. As a peripheral vasodilator, it is preferred over centrally-acting antihypertensives. Report on your application.
View details →Calan, Verelan
Verapamil is generally acceptable for FAA certification when used for hypertension. Like diltiazem, if prescribed for arrhythmia control, the underlying condition may require additional evaluation.
View details →Tenormin
Atenolol is a beta blocker generally acceptable for pilots when prescribed for hypertension. Like metoprolol, if used post-cardiac event or for arrhythmia, Special Issuance may be required.
View details →Inderal
Propranolol is a non-selective beta blocker generally acceptable for FAA certification when used for hypertension. If prescribed for performance anxiety, tremor, or migraine prevention, discuss the underlying indication with your AME.
View details →Coreg
Carvedilol is acceptable for FAA certification when used for hypertension. However, it is commonly prescribed for heart failure, which itself requires Special Issuance evaluation. The indication matters significantly.
View details →Zebeta
Bisoprolol is a selective beta blocker generally acceptable for FAA certification when used for hypertension. Report the medication and ensure no exercise intolerance or symptomatic bradycardia.
View details →Bystolic
Nebivolol is a newer selective beta blocker acceptable for FAA certification. It may have fewer fatigue-related side effects than older beta blockers, making it popular among active pilots.
View details →Microzide, HydroDIURIL
Hydrochlorothiazide (HCTZ) is one of the most commonly used diuretics and is generally acceptable for FAA certification. Pilots should be aware of electrolyte imbalances and dehydration risk, especially in hot cockpit environments.
View details →Lasix
Furosemide is generally acceptable for FAA certification, but the underlying condition requiring a loop diuretic (heart failure, edema) may require Special Issuance. The medication itself is not on the DNI list.
View details →Aldactone
Spironolactone is not on the FAA's Do Not Issue list and may be acceptable for certification. The underlying condition (heart failure, hypertension, hormonal) drives the certification pathway. Report medication and indication.
View details →Thalitone
Chlorthalidone is a thiazide-like diuretic acceptable for FAA certification. Like HCTZ, it is commonly used for hypertension and is not on the Do Not Issue list. Monitor electrolytes and hydration.
View details →Protonix
Pantoprazole is a PPI generally acceptable for FAA certification. Like omeprazole, ensure the underlying GI condition is stable and not causing symptoms that could impair flight safety.
View details →Prevacid
Lansoprazole is a PPI acceptable for FAA certification. Same pathway as omeprazole — report the medication and ensure the underlying condition is well-managed.
View details →Nexium
Esomeprazole is a PPI generally acceptable for FAA certification. Report it on your application and ensure the underlying GERD or acid reflux is well-controlled.
View details →Aciphex
Rabeprazole is a PPI acceptable for FAA medical certification. Same pathway as other PPIs — the medication itself is not an issue; focus is on the underlying GI condition being well-controlled.
View details →Pepcid
Famotidine is an H2 blocker available over the counter and is generally acceptable for pilots. It does not cause sedation and is commonly used for heartburn and GERD. Report on your application.
View details →Zantac (discontinued)
Ranitidine was an H2 blocker previously acceptable for pilots. It was withdrawn from most markets in 2020 due to NDMA contamination concerns. If still in use outside the US, same pathway as famotidine applies.
View details →Tapazole
Methimazole for hyperthyroidism is generally compatible with FAA certification once thyroid function is stable and within normal range. The pilot must be free of symptoms such as tremor, palpitations, or heat intolerance.
View details →Januvia
Sitagliptin is a DPP-4 inhibitor acceptable for FAA certification. It has a low risk of hypoglycemia when used alone, making it favorable from an aviation safety perspective. Report on your application.
View details →Actos
Pioglitazone is a thiazolidinedione approved for FAA certification when used for Type 2 diabetes. Low hypoglycemia risk as monotherapy. Report on your application with diabetes documentation.
View details →Bayer Low-Dose, Baby Aspirin
Low-dose aspirin (81mg) for cardiovascular prevention is generally acceptable for pilots. The underlying cardiovascular condition being managed may require additional evaluation, but the medication itself is not an issue.
View details →Plavix
Clopidogrel is not on the FAA DNI list and is generally acceptable. However, the underlying condition requiring antiplatelet therapy (coronary stent, stroke prevention) typically requires Special Issuance evaluation.
View details →Zyloprim
Allopurinol for gout prevention is generally compatible with FAA certification. The medication is not on the DNI list. Ensure gout is well-controlled and not causing acute flares that could impair flight duties.
View details →Colcrys, Mitigare
Colchicine for gout treatment and prevention is generally acceptable for FAA certification. During an acute gout flare, pilots should not fly due to pain and mobility impairment rather than the medication itself.
View details →Amoxil, Trimox
Amoxicillin is generally acceptable for pilots. The key consideration is the underlying infection being treated — pilots should not fly while acutely ill. Once feeling well and infection is resolving, flying is typically permissible.
View details →Zithromax, Z-Pack
Azithromycin is generally acceptable for pilots. The underlying infection is the primary concern. Do not fly while acutely ill. Once symptoms resolve and you are feeling well, flying is typically permissible.
View details →Cipro
Ciprofloxacin is generally acceptable for FAA certification. However, fluoroquinolones can cause tendon issues, CNS effects, and peripheral neuropathy. Pilots should complete the course and ensure no significant side effects before flying.
View details →Vibramycin, Doryx
Doxycycline is generally acceptable for pilots. Commonly used for infections and malaria prophylaxis. Sun sensitivity is the main side effect concern for pilots. Ensure no dizziness or visual disturbance.
View details →Keflex
Cephalexin is generally acceptable for pilots. A first-generation cephalosporin with minimal CNS effects. The underlying infection is the primary concern for flight safety, not the medication itself.
View details →Levaquin
Levofloxacin is generally acceptable for FAA certification with the same precautions as ciprofloxacin. Monitor for CNS effects, tendon issues, and peripheral neuropathy. Ground trial recommended before flying.
View details →Diflucan
Fluconazole is generally acceptable for pilots for short-term antifungal treatment. No significant CNS effects at standard doses. The underlying condition should not impair flight safety.
View details →Xalatan
Latanoprost eye drops for glaucoma are generally compatible with FAA certification. The underlying glaucoma diagnosis requires evaluation of visual fields, but the medication itself is acceptable. No systemic side effects expected.
View details →Timoptic
Timolol ophthalmic drops for glaucoma are generally acceptable for FAA certification. Although a beta blocker, systemic absorption is minimal. The underlying glaucoma requires visual field evaluation.
View details →Viagra, Revatio
Sildenafil is acceptable for FAA certification with a mandatory 8-hour wait period after each dose. Pilots must not fly within 8 hours of taking a dose due to potential visual disturbances (blue-tinted vision) and hemodynamic effects.
View details →Cialis, Adcirca
Tadalafil is acceptable for FAA certification with a mandatory wait period. For as-needed use, a 24-hour wait is required. For daily low-dose use (2.5mg or 5mg), a 7-day ground trial is required to ensure no adverse effects before flying.
View details →Aleve, Naprosyn
Naproxen is generally acceptable for pilots when used as directed. Like ibuprofen, the underlying condition being treated is the primary concern. No specific grounding period for occasional use.
View details →Bayer, Bufferin, Ecotrin
Aspirin is generally acceptable for pilots for both pain relief and cardiovascular prophylaxis. No specific grounding period. The underlying condition being treated is the primary consideration.
View details →Sudafed
Pseudoephedrine is acceptable for pilots but requires a wait period after each dose. It is a sympathomimetic that can cause increased heart rate and blood pressure. A ground trial is recommended before flying.
View details →Mucinex, Robitussin
Guaifenesin is an expectorant generally acceptable for pilots. It has no sedating properties when used alone. However, many combination products contain additional ingredients (dextromethorphan, antihistamines) that may affect flying.
View details →Robaxin
Methocarbamol is one of the few muscle relaxants that may be acceptable for FAA certification. It is less sedating than cyclobenzaprine or carisoprodol. However, a ground trial is essential to rule out individual sedation, and it should not be used while flying.
View details →ProAir, Ventolin, Proventil
Albuterol inhalers are generally compatible with FAA certification for mild, well-controlled asthma. Pilots must demonstrate adequate pulmonary function. Frequent rescue inhaler use may indicate poorly controlled asthma requiring further evaluation.
View details →Singulair
Montelukast is generally acceptable for FAA certification when used for asthma or allergic rhinitis. The FAA does note rare neuropsychiatric side effects. Report any mood changes or behavioral effects to your AME.
View details →Flovent, ArmonAir
Fluticasone inhalers are generally compatible with FAA certification for asthma maintenance therapy. Inhaled corticosteroids are preferred controller medications. Pulmonary function must meet FAA standards.
View details →Allegra
Fexofenadine is a second-generation antihistamine generally acceptable for pilots. It is non-sedating in most individuals. A ground trial is recommended to confirm no individual sedation response.
View details →Tradjenta
Linagliptin is a DPP-4 inhibitor acceptable for FAA certification. Low hypoglycemia risk and no renal dose adjustment needed. Report on your application with diabetes documentation.
View details →Onglyza
Saxagliptin is a DPP-4 inhibitor acceptable for FAA certification when used for Type 2 diabetes. Same pathway as sitagliptin — low hypoglycemia risk, report on application.
View details →Proscar, Propecia
Finasteride for BPH or hair loss is generally compatible with FAA certification. The medication has no significant CNS effects and is not on the DNI list. Report on your application.
View details →Flomax
Tamsulosin for benign prostatic hyperplasia is generally acceptable for FAA certification. The main concern is orthostatic hypotension (dizziness upon standing), which should be assessed during ground trial.
View details →Zofran
Ondansetron is generally acceptable for pilots for short-term anti-nausea use. It is non-sedating and not on the DNI list. However, the underlying condition causing nausea should be evaluated — do not fly while acutely ill.
View details →Cardura
Doxazosin is generally acceptable for FAA certification when used for BPH or hypertension. The main aviation concern is orthostatic hypotension (dizziness on standing). A ground trial is recommended.
View details →Zetia
Ezetimibe is generally compatible with FAA certification. Used alone or with statins for cholesterol management, it has a favorable side effect profile and is not on the DNI list.
View details →TriCor, Fenoglide
Fenofibrate for triglyceride management is generally compatible with FAA certification. Report the medication and ensure no significant side effects, particularly muscle pain when used with statins.
View details →Flagyl
Metronidazole is generally acceptable for pilots for short-term use. The main concern is the underlying infection. Avoid alcohol while on metronidazole due to severe interaction. Some pilots report metallic taste and mild nausea.
View details →Bactrim, Septra
TMP-SMX (Bactrim) is generally acceptable for pilots. The underlying urinary tract or other infection is the primary concern. Ensure adequate hydration and no significant side effects before flying.
View details →Macrobid, Macrodantin
Nitrofurantoin is generally acceptable for pilots for UTI treatment. Minimal systemic effects. The underlying infection is the primary concern for flight safety.
View details →Flonase, Veramyst
Fluticasone nasal spray is generally acceptable for pilots. It is a topical corticosteroid with minimal systemic absorption. No wait period or grounding required.
View details →Nasonex
Mometasone nasal spray is generally acceptable for pilots. Like fluticasone nasal, it is a topical corticosteroid with minimal systemic effects and no grounding requirement.
View details →Imodium
Loperamide is generally acceptable for pilots for short-term diarrhea management. The underlying GI condition is more important. Do not fly while experiencing active gastrointestinal illness.
View details →Prilosec OTC
OTC omeprazole is acceptable for pilots, same as prescription omeprazole. Report even OTC medications on your application. The underlying GERD should be well-controlled.
View details →Zovirax, Sitavig
Acyclovir for herpes simplex or herpes zoster is generally acceptable for FAA certification. The medication has minimal CNS effects. The underlying condition (particularly if involving the eye or causing significant pain) should be assessed.
View details →Valtrex
Valacyclovir is a prodrug of acyclovir and is generally acceptable for FAA certification. Same considerations as acyclovir — the underlying condition matters more than the medication.
View details →Carafate
Sucralfate is generally acceptable for FAA certification. Used for gastric/duodenal ulcer protection, it acts locally in the GI tract with minimal systemic absorption. Report the underlying condition.
View details →Uloric
Febuxostat for gout prevention is generally compatible with FAA certification. Same pathway as allopurinol. Report on your application and ensure gout is well-controlled.
View details →Pulmicort
Budesonide inhalers are generally compatible with FAA certification for asthma maintenance. Same pathway as fluticasone inhalers — inhaled corticosteroids are preferred controller medications.
View details →Foradil, Perforomist
Formoterol inhalers are generally compatible with FAA certification when asthma is well-controlled. Long-acting beta agonists are used as maintenance therapy and should always be used with an inhaled corticosteroid.
View details →Serevent
Salmeterol inhalers are generally compatible with FAA certification. Same pathway as formoterol — must be used with an inhaled corticosteroid. Pulmonary function must meet FAA standards.
View details →Fosamax
Alendronate for osteoporosis is generally compatible with FAA certification. The medication has no CNS effects and is not on the DNI list. Report on your application and note any GI side effects.
View details →Evista
Raloxifene for osteoporosis prevention is generally compatible with FAA certification. No significant CNS effects. The DVT risk should be discussed with your AME, but the medication itself is not on the DNI list.
View details →Celebrex
Celecoxib is a COX-2 selective NSAID generally acceptable for FAA certification. Like other NSAIDs, the underlying condition being treated is the primary concern. Report on your application.
View details →Mobic
Meloxicam is an NSAID generally acceptable for FAA certification. Same considerations as ibuprofen and naproxen — the underlying condition matters more than the medication itself.
View details →Ditropan
Oxybutynin for overactive bladder may be acceptable for FAA certification. However, anticholinergic side effects (dry mouth, blurred vision, cognitive effects in older adults) should be assessed. A ground trial is recommended.
View details →Vesicare
Solifenacin for overactive bladder is generally acceptable for FAA certification. It has fewer CNS side effects than oxybutynin. Report on your application and ensure no blurred vision or dizziness.
View details →Estrace, Vivelle, Climara
Estradiol hormone replacement therapy is generally acceptable for FAA certification. Report on your application. The underlying condition and any thromboembolic risk should be discussed with your AME.
View details →Linzess
Linaclotide for IBS with constipation is generally compatible with FAA certification. The medication acts locally in the gut with minimal systemic absorption. Report the underlying condition on your application.
View details →Colace
Docusate sodium is an OTC stool softener that is generally acceptable for pilots. No CNS effects, no wait period required. Report on your application if using regularly.
View details →MiraLAX
MiraLAX is an OTC osmotic laxative generally acceptable for pilots. No systemic absorption. Ensure you are not experiencing active GI symptoms while flying.
View details →Various OTC brands
Vitamin D supplementation is generally acceptable for pilots. No aviation safety concerns. Report on your application if prescribed (as opposed to OTC supplement), and note the underlying reason for supplementation.
View details →Lovaza, Vascepa, OTC Fish Oil
Fish oil and omega-3 supplements are generally acceptable for pilots. Prescription-strength versions (Lovaza, Vascepa) for triglyceride management are also acceptable. Report on your application.
View details →Various OTC brands
Melatonin is generally acceptable for FAA certification, but pilots should not fly while under its sedating effects. A wait period after the last dose is recommended. It is commonly used by pilots for circadian rhythm adjustment.
View details →Voltaren, Cataflam
Diclofenac is an NSAID generally acceptable for FAA certification, whether oral or topical (Voltaren gel). The underlying condition is the primary concern. Topical formulations have minimal systemic absorption.
View details →Monopril
Fosinopril is an ACE inhibitor generally compatible with FAA medical certification. Blood pressure must be well-controlled and the pilot should not experience significant side effects such as dizziness or persistent cough.
View details →Accupril
Quinapril is an ACE inhibitor acceptable for FAA certification when blood pressure is controlled. Same pathway as other ACE inhibitors — report the medication and demonstrate stable blood pressure.
View details →Mavik
Trandolapril is an ACE inhibitor generally compatible with FAA certification. Report the medication and ensure blood pressure is well-controlled with no significant side effects.
View details →Teveten
Eprosartan is an ARB acceptable for FAA medical certification. Like other ARBs, it is not on the Do Not Issue list. Report on your application and demonstrate controlled blood pressure.
View details →Plendil
Felodipine is a dihydropyridine calcium channel blocker generally acceptable for FAA certification. It is a peripheral vasodilator used for hypertension and is not on the Do Not Issue list.
View details →DynaCirc
Isradipine is a calcium channel blocker acceptable for FAA certification when used for hypertension. Report the medication and ensure blood pressure is controlled without significant side effects.
View details →Cardene
Nicardipine is a calcium channel blocker generally compatible with FAA certification for hypertension. It is a peripheral vasodilator and is not on the Do Not Issue list.
View details →Sular
Nisoldipine is a dihydropyridine calcium channel blocker acceptable for FAA certification. Same pathway as other CCBs — report the medication and demonstrate controlled blood pressure.
View details →Trandate
Labetalol is a combined alpha- and beta-blocker generally acceptable for FAA certification when used for hypertension. Report the medication and ensure no exercise intolerance, orthostatic hypotension, or excessive fatigue.
View details →Corgard
Nadolol is a non-selective beta blocker generally acceptable for FAA certification when prescribed for hypertension. If used for cardiac arrhythmia, the underlying condition may require Special Issuance evaluation.
View details →Visken
Pindolol is a beta blocker with intrinsic sympathomimetic activity, generally acceptable for FAA certification when used for hypertension. Less likely to cause bradycardia than other beta blockers.
View details →Sectral
Acebutolol is a cardioselective beta blocker generally acceptable for FAA certification when used for hypertension. If prescribed for ventricular arrhythmias, the underlying condition may require Special Issuance evaluation.
View details →Nesina
Alogliptin is a DPP-4 inhibitor acceptable for FAA certification. Same pathway as sitagliptin — low hypoglycemia risk and straightforward certification with proper diabetes documentation.
View details →Cytomel
Liothyronine (T3) for hypothyroidism is generally compatible with FAA certification when thyroid levels are stable. Less commonly used than levothyroxine, but follows the same pathway. Stable TSH and free T3/T4 levels are required.
View details →Atrovent
Ipratropium inhalers are generally acceptable for FAA certification. Used for COPD and sometimes asthma, the medication has minimal systemic effects. Pulmonary function testing must meet FAA standards.
View details →Accolate
Zafirlukast is a leukotriene receptor antagonist acceptable for FAA certification. Same class as montelukast with a similar safety profile for aviation. Report on your application.
View details →Dexilant
Dexlansoprazole is a PPI acceptable for FAA certification. Same pathway as other PPIs — report the medication and ensure the underlying GI condition is well-managed.
View details →Relafen
Nabumetone is a prescription NSAID generally acceptable for FAA certification. It is a prodrug with lower GI toxicity than some NSAIDs. The underlying condition being treated is the primary concern.
View details →Feldene
Piroxicam is a prescription NSAID generally acceptable for FAA certification. It has a long half-life allowing once-daily dosing. Same pathway as other NSAIDs — underlying condition is the primary consideration.
View details →Toradol
Ketorolac is a potent prescription NSAID for short-term use generally acceptable for FAA certification. Pilots should not fly while in acute pain requiring ketorolac. Once the acute episode resolves, flying is permissible.
View details →Avodart
Dutasteride is generally acceptable for FAA certification when used for BPH. Same pathway as finasteride — no CNS effects and not on the DNI list. Report on your application.
View details →Rapaflo
Silodosin is a highly selective alpha blocker for BPH generally acceptable for FAA certification. Very uroselective with minimal blood pressure effects. Report on your application.
View details →Uroxatral
Alfuzosin is an alpha blocker for BPH generally compatible with FAA certification. It is uroselective and less likely to cause systemic hypotension than older alpha blockers. Report the medication on your application.
View details →Hytrin
Terazosin is an alpha blocker acceptable for FAA certification for BPH or hypertension. It can cause orthostatic hypotension and a ground trial is recommended before flying.
View details →Alphagan, Alphagan P
Brimonidine eye drops for glaucoma are generally compatible with FAA certification. Topical use has minimal systemic absorption. The underlying glaucoma diagnosis requires visual field evaluation to meet FAA standards.
View details →Trusopt
Dorzolamide eye drops for glaucoma are generally acceptable for FAA certification. Topical carbonic anhydrase inhibitors have minimal systemic effects. Visual field evaluation is required for the underlying glaucoma.
View details →These medications may be approved through the FAA's Special Issuance process. Additional documentation, wait periods, or monitoring may be required.
Zoloft
Sertraline is one of four SSRI antidepressants the FAA may approve through the Special Issuance process. Pilots must be stable on the same dose for at least 6 months before applying, with no disqualifying side effects.
View details →Prozac
Fluoxetine was one of the first four SSRIs the FAA approved in 2010. It is available through the Special Issuance process with the standard SSRI protocol requirements.
View details →Celexa
Citalopram is one of four FAA-approved SSRIs. Same Special Issuance protocol as sertraline and fluoxetine — 6 months stability, CogScreen testing, ongoing monitoring.
View details →Lexapro
Escitalopram is one of four FAA-approved SSRIs available through the Special Issuance process. Same protocol as sertraline — requires 6 months of stability on the same dose, CogScreen testing, and ongoing AME monitoring.
View details →Glucophage, Fortamet
Metformin is approved for pilots with Type 2 diabetes under the Special Issuance process. Pilots must demonstrate stable blood glucose control and absence of significant diabetes-related complications.
View details →Glucotrol
Glipizide is conditionally approved for pilots with Type 2 diabetes. Because sulfonylureas can cause hypoglycemia, the FAA requires additional glucose monitoring documentation compared to metformin alone.
View details →Humalog, Lantus, Novolog, Tresiba
Since November 2019, the FAA allows insulin-treated pilots to hold 1st, 2nd, and 3rd class medical certificates through a rigorous Special Issuance protocol. This was a landmark policy change. The process requires extensive documentation and continuous glucose monitoring.
View details →Coumadin, Jantoven
Warfarin may be approved through Special Issuance, depending on the underlying condition requiring anticoagulation. The INR must be stable and within therapeutic range. The underlying condition (DVT, AFib, mechanical valve) drives the certification pathway.
View details →Ambien, Ambien CR
Zolpidem (Ambien) is a Do Not Fly medication with a mandatory 24-hour wait period after each dose. Occasional use is permitted, but daily or nightly use is not allowed for pilots. Pilots may hold a medical certificate while using zolpidem occasionally, but must not fly within 24 hours of taking a dose.
View details →Jardiance
Empagliflozin is an SGLT2 inhibitor that may be approved for pilots with Type 2 diabetes through the Special Issuance process. While it has cardiovascular benefits, the FAA requires documentation of stable glucose control and absence of diabetic ketoacidosis risk.
View details →Victoza, Saxenda
Liraglutide is a GLP-1 receptor agonist that may be approved through the FAA diabetes Special Issuance pathway. Low hypoglycemia risk as monotherapy. When branded as Saxenda for weight loss, the indication may affect the pathway.
View details →Trulicity
Dulaglutide is a weekly GLP-1 agonist that may be approved through the FAA diabetes Special Issuance process. Same pathway as other diabetes medications — stable glucose control and appropriate monitoring required.
View details →Invokana
Canagliflozin is an SGLT2 inhibitor available through the FAA diabetes Special Issuance pathway. Like empagliflozin, documentation must confirm no DKA risk and stable glucose control.
View details →Farxiga
Dapagliflozin is an SGLT2 inhibitor that may be approved through the FAA diabetes Special Issuance process. Standard diabetes pathway requirements apply — stable glucose, A1C monitoring, and no DKA episodes.
View details →Eliquis
Apixaban may be approved through Special Issuance depending on the underlying condition requiring anticoagulation (atrial fibrillation, DVT/PE). The medication itself is increasingly accepted as an alternative to warfarin, but the underlying condition drives the pathway.
View details →Xarelto
Rivaroxaban may be approved through Special Issuance depending on the underlying indication. Like apixaban, the DOAC itself is not specifically prohibited, but the condition requiring anticoagulation must be certifiable.
View details →Pradaxa
Dabigatran may be approved through Special Issuance depending on the underlying condition. Same pathway as other DOACs — the anticoagulant is not specifically prohibited, but the condition requiring it must be certifiable.
View details →Cordarone, Pacerone
Amiodarone requires Special Issuance evaluation. The underlying arrhythmia is the primary concern, and amiodarone's significant side effect profile (thyroid, pulmonary, liver, neurological) requires extensive monitoring. Certification is possible but complex.
View details →Tambocor
Flecainide requires Special Issuance evaluation. Used for atrial fibrillation and supraventricular tachycardia, the underlying arrhythmia and the medication's proarrhythmic potential both require thorough cardiac evaluation.
View details →Betapace, Sorine
Sotalol requires Special Issuance evaluation due to its antiarrhythmic properties and the underlying cardiac condition. It combines beta blocker and class III antiarrhythmic effects, requiring thorough cardiac workup.
View details →Lamictal
Lamotrigine may be conditionally approved depending on the indication. If used for seizures, the seizure disorder itself is typically disqualifying. If used as a mood stabilizer for bipolar disorder, that condition is also disqualifying. Some off-label uses may have a pathway through Special Issuance.
View details →Synthroid, Levoxyl
Levothyroxine after thyroidectomy for thyroid cancer requires Special Issuance evaluation. While levothyroxine itself is approved, the cancer history necessitates documentation of remission status, surveillance labs, and endocrinologist follow-up.
View details →Restoril
Temazepam (Restoril) is listed on the FAA sleep aids page with a mandatory 72-hour wait period after each dose. Despite being a benzodiazepine, the FAA permits occasional use for sleep with this extended wait period. Daily or nightly use is not allowed. Note: other benzodiazepines used for anxiety (alprazolam, diazepam, lorazepam, clonazepam) remain fully disqualifying.
View details →Lunesta
Eszopiclone (Lunesta) is a Do Not Fly medication with a mandatory 30-hour wait period after each dose. Occasional use is permitted, but daily or nightly use is not allowed for pilots. The longer wait period compared to zolpidem reflects its longer half-life.
View details →Sonata
Zaleplon (Sonata) is a Do Not Fly medication with a mandatory 12-hour wait period after each dose — the shortest wait of all FAA-listed sleep aids due to its very short half-life. Occasional use is permitted, but daily or nightly use is not allowed for pilots.
View details →Trexall, Rheumatrex
Methotrexate may be conditionally approved depending on the underlying autoimmune condition. Used for rheumatoid arthritis and psoriasis, the medication requires monitoring but is not specifically on the DNI list. The underlying condition drives the pathway.
View details →Humira
Adalimumab is a biologic medication that may be conditionally approved depending on the underlying autoimmune condition and infection risk. The medication itself is not on the DNI list, but the condition and immunosuppression require evaluation.
View details →Deltasone, Rayos
Prednisone is conditionally acceptable. Short-term courses (e.g., for asthma exacerbation) may be acceptable after the course is completed and symptoms resolve. Chronic systemic steroid use requires evaluation for side effects including mood changes, glucose elevation, and adrenal suppression.
View details →Spiriva
Tiotropium may be conditionally approved depending on the severity of the underlying COPD or asthma. Mild, well-controlled cases with adequate pulmonary function may qualify. Severe COPD is generally disqualifying.
View details →Lanoxin
Digoxin requires Special Issuance evaluation. Used for heart failure and atrial fibrillation, both the medication and underlying cardiac condition require thorough evaluation. Narrow therapeutic index makes monitoring critical.
View details →Multaq
Dronedarone requires Special Issuance evaluation. Used for atrial fibrillation, the underlying arrhythmia and medication both require comprehensive cardiac workup for FAA certification.
View details →Rhythmol
Propafenone requires Special Issuance evaluation. Used for atrial fibrillation and supraventricular tachycardia, the medication and underlying arrhythmia require comprehensive cardiac documentation.
View details →Ozempic, Rybelsus
Semaglutide for Type 2 diabetes (Ozempic/Rybelsus) may be approved through the FAA diabetes Special Issuance pathway. This is distinct from the weight loss indication (Wegovy). Standard diabetes monitoring and documentation requirements apply.
View details →AndroGel, Testim, Depo-Testosterone
Testosterone replacement therapy may be conditionally acceptable for FAA certification. Testosterone levels must be within normal physiologic range and the underlying hypogonadism must be documented. Supraphysiologic dosing is not acceptable.
View details →DDAVP, Stimate
Desmopressin may be conditionally approved depending on the underlying condition (diabetes insipidus, bedwetting, von Willebrand disease). The condition and electrolyte stability determine the certification pathway.
View details →Plaquenil
Hydroxychloroquine may be conditionally approved depending on the underlying autoimmune condition. The main aviation concern is retinal toxicity with long-term use, which can affect visual fields. Regular ophthalmologic screening is required.
View details →Arava
Leflunomide may be conditionally approved depending on the underlying rheumatoid arthritis severity and medication side effects. Not on the DNI list, but the underlying condition and immunosuppression require evaluation.
View details →Azulfidine
Sulfasalazine may be conditionally approved depending on whether used for rheumatoid arthritis or inflammatory bowel disease. The medication itself is not on the DNI list, but the underlying condition drives the certification pathway.
View details →Asacol, Lialda, Pentasa
Mesalamine for ulcerative colitis or Crohn's disease may be conditionally approved. The medication itself is not on the DNI list, but the underlying IBD severity and symptom control determine the certification pathway.
View details →Imuran, Azasan
Azathioprine may be conditionally approved depending on the underlying autoimmune condition. As an immunosuppressant, infection risk and the underlying disease activity must be well-documented for certification.
View details →Prograf
Tacrolimus for organ transplant recipients may be considered through Special Issuance, though the pathway is complex. Organ transplant certification is one of the most challenging Special Issuance categories, requiring extensive documentation of graft function and overall health.
View details →CellCept, Myfortic
Mycophenolate may be conditionally approved through Special Issuance depending on whether used for transplant or autoimmune disease. Same extensive evaluation pathway as other immunosuppressants.
View details →Ranexa
Ranolazine requires Special Issuance evaluation. Used as second-line angina therapy, the underlying coronary disease must be thoroughly documented. The medication itself has QT prolongation risk.
View details →Corlanor
Ivabradine requires Special Issuance evaluation. Used for heart failure with reduced ejection fraction, the underlying cardiac condition is the primary concern. Comprehensive cardiac documentation required.
View details →Entresto
Sacubitril-valsartan requires Special Issuance evaluation. As a heart failure medication, the underlying cardiac condition must be thoroughly documented including ejection fraction, functional status, and exercise tolerance.
View details →Savaysa
Edoxaban may be approved through Special Issuance depending on the underlying condition requiring anticoagulation. Like other DOACs, the medication itself is not specifically prohibited, but the underlying condition must be certifiable.
View details →Tikosyn
Dofetilide requires Special Issuance evaluation. Used for atrial fibrillation and atrial flutter, the underlying arrhythmia and the medication's QT-prolonging potential both require thorough cardiac evaluation and monitoring.
View details →Theo-24, Elixophyllin
Theophylline has a narrow therapeutic index and can cause significant side effects at supratherapeutic levels. The FAA may require documentation of stable therapeutic levels and absence of CNS side effects such as tremor, insomnia, or seizures.
View details →Accutane, Claravis, Absorica
Isotretinoin may be acceptable for FAA certification with specific precautions. It can cause night vision impairment, mood changes, and musculoskeletal symptoms. A ground trial is essential, and the pilot must report any visual disturbances or psychiatric side effects to their AME.
View details →These medications are on the FAA's Do Not Issue or Do Not Fly lists. A washout period and evaluation are typically required after discontinuation.
Adderall, Adderall XR
Adderall and other amphetamine-based ADHD medications are currently disqualifying for FAA medical certification. The underlying ADHD diagnosis itself requires a Special Issuance evaluation. Legislative efforts are underway to potentially expand approved ADHD treatment options.
View details →Ritalin, Concerta, Focalin
Methylphenidate and all stimulant ADHD medications are on the FAA's Do Not Issue list. Like Adderall, the ADHD diagnosis requires separate evaluation even if medication is discontinued.
View details →Xanax
Alprazolam and all benzodiazepines are on the FAA's Do Not Issue list. These medications are disqualifying due to their sedating effects and potential for dependence. A significant washout period is required after discontinuation.
View details →Valium
Diazepam is a benzodiazepine and is on the FAA's Do Not Issue list. All benzodiazepines are disqualifying regardless of indication (anxiety, muscle spasm, seizure prevention).
View details →Ultram, ConZip
Tramadol and all opioid medications are on the FAA's Do Not Issue list. Chronic opioid use is disqualifying. The underlying pain condition may also require evaluation.
View details →Neurontin, Gralise
Gabapentin is on the FAA's Do Not Issue list due to its CNS effects. It is disqualifying regardless of whether it is prescribed for seizures, neuropathic pain, or off-label uses like anxiety.
View details →Imitrex
Sumatriptan is on the FAA's Do Not Fly table — pilots must not fly within 24 hours of taking a dose. Chronic migraines requiring frequent triptan use may require Special Issuance evaluation. Occasional migraine with infrequent triptan use may be certifiable.
View details →Medical marijuana, THC products, CBD with THC
Marijuana in all forms — including medical marijuana legal under state law — is disqualifying for FAA medical certification. The FAA follows federal law, under which marijuana remains a Schedule I controlled substance. CBD products containing any THC are also problematic.
View details →Provigil
Modafinil is on the FAA's Do Not Issue list. It is disqualifying regardless of indication — whether prescribed for narcolepsy, shift work disorder, or off-label ADHD use. The underlying sleep disorder also requires evaluation.
View details →Vicodin, Norco, Lortab
Hydrocodone and all opioid pain medications are on the FAA's Do Not Issue list. Short-term post-surgical use requires a wait period; chronic use is disqualifying and the underlying pain condition requires evaluation.
View details →Ativan
Lorazepam is a benzodiazepine on the FAA's Do Not Issue list. All benzodiazepines are disqualifying due to sedation, cognitive impairment, and dependence risk. A significant washout period and substance evaluation may be required after discontinuation.
View details →Klonopin
Clonazepam is a benzodiazepine on the FAA's DNI list. Whether prescribed for anxiety or seizures, it is disqualifying. The underlying condition also requires evaluation.
View details →OxyContin, Percocet, Roxicodone
Oxycodone is on the FAA's DNI list. All opioids are disqualifying for FAA certification. Chronic use requires extended washout and potential substance evaluation. The underlying pain condition also needs assessment.
View details →MS Contin, Kadian
Morphine is on the FAA's DNI list. All opioids are disqualifying. Chronic morphine use requires extensive washout period and likely substance evaluation before any certification can be considered.
View details →Tylenol with Codeine
Codeine is on the FAA's DNI list. Even in cough suppressant formulations, codeine is an opioid and is disqualifying. Pilots should use non-opioid cough suppressants.
View details →Duragesic, Actiq, Subsys
Fentanyl in all forms (patches, lozenges, etc.) is on the FAA's DNI list. As a potent opioid, it is absolutely disqualifying. Extended washout and substance evaluation required after discontinuation.
View details →Suboxone, Subutex, Sublocade
Buprenorphine is on the FAA's DNI list. Whether used for chronic pain or opioid use disorder treatment, it is disqualifying. The underlying condition (opioid dependence or chronic pain) also requires separate evaluation.
View details →Belsomra
Suvorexant is on the FAA's DNI list. As a dual orexin receptor antagonist used for insomnia, it is disqualifying due to its sedating mechanism of action.
View details →Seroquel
Quetiapine is on the FAA's DNI list. All antipsychotic medications are disqualifying. Even low-dose quetiapine prescribed off-label for sleep is disqualifying. The underlying condition also requires evaluation.
View details →Zyprexa
Olanzapine is on the FAA's DNI list. All antipsychotic medications are disqualifying regardless of indication. The underlying psychiatric condition also requires evaluation.
View details →Risperdal
Risperidone is on the FAA's DNI list. All antipsychotic medications are disqualifying for aviation certification due to sedation, cognitive effects, and the underlying conditions they treat.
View details →Abilify
Aripiprazole is on the FAA's DNI list. Despite being considered less sedating than other antipsychotics, all medications in this class are disqualifying. Even when used as augmentation for depression, it remains disqualifying.
View details →Lithobid, Eskalith
Lithium is on the FAA's DNI list. As a mood stabilizer for bipolar disorder, both the medication and the underlying condition are disqualifying. Lithium's narrow therapeutic index and potential for toxicity make it incompatible with aviation.
View details →Depakote, Depakene
Valproic acid is on the FAA's DNI list. Whether prescribed for seizures, bipolar disorder, or migraine prevention, it is disqualifying. The underlying conditions it treats are also typically disqualifying.
View details →Tegretol, Carbatrol
Carbamazepine is on the FAA's DNI list. Used for seizures, bipolar disorder, and trigeminal neuralgia, it is disqualifying regardless of indication. Both the medication and underlying conditions are problematic for certification.
View details →Vyvanse
Lisdexamfetamine (Vyvanse) is on the FAA's DNI list. As an amphetamine prodrug for ADHD, it is disqualifying like all stimulant medications. The ADHD diagnosis itself also requires separate evaluation.
View details →Strattera
Atomoxetine is on the FAA's DNI list despite being a non-stimulant ADHD medication. All ADHD medications are currently disqualifying. The underlying ADHD diagnosis requires separate Special Issuance evaluation.
View details →BuSpar
Buspirone is on the FAA's DNI list. Although it is a non-benzodiazepine anxiolytic with less sedation risk, it is still disqualifying for aviation. The underlying anxiety disorder also requires evaluation.
View details →Flexeril, Amrix
Cyclobenzaprine is on the FAA's DNI list. It is structurally related to tricyclic antidepressants and causes significant sedation. All centrally-acting muscle relaxants are disqualifying for aviation.
View details →Soma
Carisoprodol is on the FAA's DNI list. It is a controlled substance (Schedule IV) with significant sedation and abuse potential. It is metabolized to meprobamate, a barbiturate-like substance.
View details →Zanaflex
Tizanidine is on the FAA's DNI list. As a centrally-acting muscle relaxant, it causes sedation and hypotension that are incompatible with safe flight operations.
View details →Lioresal, Gablofen
Baclofen is on the FAA's DNI list. It is a centrally-acting muscle relaxant with sedating effects that are disqualifying for aviation. The underlying spasticity condition may also affect certification.
View details →Topamax, Qudexy
Topiramate is on the FAA's DNI list. Whether prescribed for migraine prevention, seizures, or weight loss, it is disqualifying due to cognitive side effects ('brain fog') and its anticonvulsant classification.
View details →Adipex-P, Lomaira
Phentermine is on the FAA's DNI list. As a sympathomimetic amine chemically related to amphetamine, it is disqualifying. It can cause cardiovascular effects, insomnia, and CNS stimulation incompatible with aviation safety.
View details →Wegovy
Semaglutide for weight loss (Wegovy) is currently disqualifying for FAA certification. While semaglutide for diabetes (Ozempic) may be considered under the diabetes Special Issuance pathway, the weight loss indication does not have an established FAA pathway. This is an evolving area — consult your AME.
View details →Wellbutrin, Zyban
Bupropion is on the FAA's Do Not Issue list. It is NOT one of the four approved SSRI antidepressants (sertraline, fluoxetine, citalopram, escitalopram). Bupropion is an NDRI with a different mechanism and seizure risk, and it does not qualify under the SSRI Special Issuance protocol.
View details →Benadryl
Diphenhydramine is a first-generation antihistamine that is NOT acceptable for flying. Its significant sedating effects make it incompatible with aviation. Pilots must wait at least 60 hours after the last dose before flying.
View details →Reglan
Metoclopramide is on the FAA's DNI list due to its CNS effects including drowsiness, restlessness, and risk of tardive dyskinesia. Pilots should use alternative antiemetics like ondansetron.
View details →Lyrica
Pregabalin is on the FAA's DNI list. Like gabapentin, it has significant CNS effects including dizziness, somnolence, and cognitive impairment. It is disqualifying regardless of indication.
View details →Cymbalta
Duloxetine is on the FAA's DNI list. As an SNRI, it is not one of the four approved SSRIs. It is disqualifying regardless of whether prescribed for depression, anxiety, neuropathic pain, or fibromyalgia.
View details →Effexor, Effexor XR
Venlafaxine is on the FAA's DNI list. As an SNRI, it does not qualify under the SSRI Special Issuance protocol. Pilots may need to discuss switching to an approved SSRI with their psychiatrist and AME.
View details →Desyrel
Trazodone is on the FAA's DNI list. Whether prescribed for depression or insomnia, it is disqualifying due to its sedating effects. It is not one of the four approved SSRIs.
View details →Remeron
Mirtazapine is on the FAA's DNI list. It causes significant sedation and weight gain. It is not one of the four approved SSRIs and is disqualifying for aviation certification.
View details →Elavil
Amitriptyline is on the FAA's DNI list. All tricyclic antidepressants are disqualifying due to their sedating, anticholinergic, and cardiac effects. Even low doses for migraine or neuropathy are disqualifying.
View details →Pamelor
Nortriptyline is on the FAA's DNI list. Like all tricyclic antidepressants, it is disqualifying regardless of indication (depression, neuropathic pain, migraine prevention).
View details →Vistaril, Atarax
Hydroxyzine is disqualifying for FAA certification. As a first-generation antihistamine with significant sedating properties, it is used for anxiety and insomnia. Both the sedation and the underlying anxiety condition require evaluation.
View details →Catapres, Kapvay
Clonidine is on the FAA's DNI list. As a centrally-acting antihypertensive, it causes significant sedation, drowsiness, and cognitive effects. Whether prescribed for hypertension or ADHD, it is disqualifying.
View details →Keppra
Levetiracetam is on the FAA's DNI list. All anticonvulsant medications are disqualifying. The underlying seizure disorder is also independently disqualifying for FAA certification.
View details →Dilantin
Phenytoin is on the FAA's DNI list. All anticonvulsant medications are disqualifying. The underlying seizure disorder is independently disqualifying.
View details →Trileptal
Oxcarbazepine is on the FAA's DNI list. Like all anticonvulsants, it is disqualifying regardless of indication (seizures, bipolar disorder, neuropathic pain).
View details →Paxil, Pexeva
Paroxetine is an SSRI but is NOT one of the four FAA-approved SSRIs. Despite being in the SSRI class, paroxetine is disqualifying due to its shorter half-life, more significant discontinuation syndrome, and anticholinergic effects. Only fluoxetine, sertraline, citalopram, and escitalopram are approved.
View details →Luvox
Fluvoxamine is an SSRI but is NOT one of the four FAA-approved SSRIs. It is disqualifying despite being in the same drug class. Pilots may need to discuss transitioning to an approved SSRI.
View details →Dexedrine, Zenzedi
Dextroamphetamine is on the FAA's DNI list. All amphetamine-based ADHD medications are disqualifying. The ADHD diagnosis itself also requires Special Issuance evaluation.
View details →Intuniv, Tenex
Guanfacine is on the FAA's DNI list. Whether prescribed for ADHD or hypertension, it is a centrally-acting agent that causes sedation and cognitive effects incompatible with aviation.
View details →Maxalt
Rizatriptan is a triptan on the FAA's Do Not Fly table. Same restrictions as sumatriptan — do not fly within 24 hours of a dose. Chronic migraine requiring frequent triptan use may need Special Issuance evaluation.
View details →Lyrica
Pregabalin prescribed for fibromyalgia is still on the FAA's DNI list. The indication does not change its disqualifying status. Fibromyalgia itself may also require evaluation depending on severity.
View details →Lomotil
Diphenoxylate-atropine (Lomotil) is disqualifying as it contains an opioid derivative. Pilots should use loperamide (Imodium) as an alternative antidiarrheal that is generally acceptable.
View details →Phenergan
Promethazine is disqualifying for FAA certification. As a phenothiazine with significant sedating properties, it is incompatible with aviation. Use ondansetron (Zofran) as a non-sedating antiemetic alternative.
View details →Transderm Scop
Scopolamine patches are disqualifying for pilots. Despite being used for motion sickness, scopolamine causes significant anticholinergic effects including blurred vision, drowsiness, and disorientation that are incompatible with aviation.
View details →Antivert, Bonine, Dramamine Less Drowsy
Meclizine is disqualifying for pilots. Although marketed as 'less drowsy,' it is still a first-generation antihistamine with sedating properties. The underlying vertigo or motion sickness also raises flight safety concerns.
View details →Horizant
Gabapentin enacarbil is on the FAA's DNI list, same as gabapentin. Used for restless legs syndrome, both the medication and the sleep-disrupting condition require evaluation. The underlying RLS may affect sleep quality and fitness to fly.
View details →Nitrostat, Nitro-Dur
Nitroglycerin and all nitrate medications are explicitly listed as "not allowed" on the FAA AME Guide antihypertensives page. The use of nitrates indicates underlying coronary artery disease requiring active angina management, which is disqualifying. Pilots with CAD who no longer require nitrates may pursue Special Issuance for the underlying cardiac condition.
View details →Imdur, Monoket
Isosorbide mononitrate and all nitrate medications are explicitly listed as "not allowed" on the FAA AME Guide antihypertensives page. Chronic nitrate use for angina prevention indicates active coronary artery disease management, which is disqualifying. Pilots may pursue Special Issuance for the underlying CAD if nitrates are discontinued.
View details →Bentyl
Dicyclomine is on the FAA's DNI list due to its anticholinergic effects which can cause drowsiness, blurred vision, dizziness, and cognitive impairment. These effects are incompatible with safe flight operations.
View details →Levsin, Anaspaz
Hyoscyamine is on the FAA's DNI list due to anticholinergic effects including blurred vision, drowsiness, dizziness, and cognitive impairment that are incompatible with aviation safety.
View details →Sinequan, Silenor
Doxepin is on the FAA's DNI list. Whether used at antidepressant doses (Sinequan) or low doses for insomnia (Silenor), it is disqualifying. All tricyclic antidepressants are incompatible with aviation.
View details →Detrol, Detrol LA
Tolterodine is on the FAA's DNI list due to anticholinergic effects. Although marketed as having fewer CNS effects than oxybutynin, it still causes blurred vision and drowsiness that are incompatible with aviation safety.
View details →The U.S. Federal Aviation Administration does not publish a comprehensive list of “approved” medications for pilots. The information in this database represents our interpretation of publicly available FAA guidance documents including the AME Guide, Do-Not-Issue/Do-Not-Fly tables, and related Advisory Circulars. It is provided for informational and educational purposes only.
FAR regulations (61.53, 67.113, 67.213, 67.313, and 91.17) prohibit exercising pilot privileges while using any medication or substance that affects your faculties in a way contrary to safety. The primary issue with the FAA is always whether the underlying medical condition — not just the medication — is compatible with safe flight.
This database is not a substitute for consultation with a qualified Aviation Medical Examiner (AME). You should only start, stop, or change medications after consulting with your treating physician. FAA policies are subject to change without notice. ClearedMed is not affiliated with or endorsed by the FAA.